Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Summary
- Eligibility
- for people ages 6-17 (full criteria)
- Location
- at UC Davis
- Dates
- study startedcompletion around
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Pfizer
- Links
- To obtain contact information for a study center near you, click here.
- ID
- NCT04743141
- Phase
- Phase 3 research study
- Study Type
- Interventional
- Participants
- Expecting 200 study participants
- Last Updated